{
    "@context": {
        "schema": "https://schema.org/",
        "dct": "http://purl.org/dc/terms/",
        "hg": "https://hormuz.group/data/ns#"
    },
    "id": "hg:company:dana-pharmaceutical-company",
    "identifier": "hg:company:dana-pharmaceutical-company",
    "dataset_type": "entity_dataset",
    "entity_type": "company",
    "data_version": "2.0",
    "generated_by": "Hormuz Data Layer 0.2.1",
    "generated_at": "2026-07-04T02:51:17+00:00",
    "name": "Dana Pharmaceutical Company",
    "slug": "dana-pharmaceutical-company",
    "status": "publish",
    "url": "https://hormuz.group/companies/dana-pharmaceutical-company/",
    "json_url": "https://hormuz.group/wp-content/uploads/hormuz-data/cpt/company/dana-pharmaceutical-company.json",
    "rest_url": "https://hormuz.group/wp-json/hormuz-data/v1/cpt/company/dana-pharmaceutical-company",
    "summary": "",
    "machine_summary": "Dana Pharmaceutical Company Dana Pharmaceutical Company is a listed Tabriz-based pharmaceutical manufacturer and one of Iran's major antibiotic and soft-gel producers. In the Hormuz Group company graph, it matters because it connects East Azerbaijan's industrial base, API production, finished antibiotic supply, sterile production, pharmaceutical exports, listed-company disclosure, and import substitution in medicine manufacturing. Its scale makes it relevant to both healthcare access and capital-market monitoring. Dana Pharmaceutical is relevant for investors assessing Iran's listed pharmaceutical sector, antibiotic API localization, sterile-drug capacity, export potential, healthcare supply resilience, and the economics of large drug manufacturers outside Tehran. It can support analysis of medicine shortages, API dependence, pricing regulation, distributor receivables, GMP standards, and foreign-currency exposure. Due diligence should review updated Codal disclosures, production-line utilization, API sourcing, export registrations, product mix, regulatory compliance, quality certifications, working capital, shareholder structure, energy and water reliability, and exposure to sanctions-related payment or supplier constraints. Dana Pharmaceutical Company manufactures active pharmaceutical ingredients and finished pharmaceutical products, with emphasis on antibiotic APIs, oral and sterile antibiotics, injectable vials, soft-gel capsules, hard capsules, tablets, oral suspensions, sterile drops, sterile water for injection, eye drops, cardiovascular products, gastrointestinal products, supplements, and selected biotechnology or pharmaceutical development categories. province: East Azerbaijan industry: Healthcare & Pharma, Manufacturing, Pharmaceuticals market: Consumer Demand, Healthcare, Materials, Supply Chains challenges: Compliance, Import Dependence, Supply Shortage, Technology Gap company_type: Manufacturer city: Tabriz",
    "published_at": "2026-06-28T20:28:55+00:00",
    "modified_at": "2026-06-28T20:28:55+00:00",
    "taxonomies": {
        "province": [
            {
                "id": 8,
                "name": "East Azerbaijan",
                "slug": "east-azerbaijan",
                "url": "https://hormuz.group/provinces/east-azerbaijan/"
            }
        ],
        "industry": [
            {
                "id": 21,
                "name": "Healthcare & Pharma",
                "slug": "healthcare-pharma",
                "url": "https://hormuz.group/industry/healthcare-pharma/"
            },
            {
                "id": 16,
                "name": "Manufacturing",
                "slug": "manufacturing",
                "url": "https://hormuz.group/industry/manufacturing/"
            },
            {
                "id": 121,
                "name": "Pharmaceuticals",
                "slug": "pharmaceuticals",
                "url": "https://hormuz.group/industry/healthcare-pharma/pharmaceuticals/"
            }
        ],
        "market": [
            {
                "id": 34,
                "name": "Consumer Demand",
                "slug": "consumer-demand",
                "url": "https://hormuz.group/market/consumer-demand/"
            },
            {
                "id": 69,
                "name": "Healthcare",
                "slug": "healthcare",
                "url": "https://hormuz.group/market/consumer-demand/healthcare/"
            },
            {
                "id": 73,
                "name": "Materials",
                "slug": "materials",
                "url": "https://hormuz.group/market/enterprise-demand/materials/"
            },
            {
                "id": 76,
                "name": "Supply Chains",
                "slug": "supply-chains",
                "url": "https://hormuz.group/market/enterprise-demand/supply-chains/"
            }
        ],
        "challenges": [
            {
                "id": 164,
                "name": "Compliance",
                "slug": "compliance",
                "url": "https://hormuz.group/challenges/regulatory-barriers/compliance/"
            },
            {
                "id": 176,
                "name": "Import Dependence",
                "slug": "import-dependence",
                "url": "https://hormuz.group/challenges/market-gaps/import-dependence/"
            },
            {
                "id": 177,
                "name": "Supply Shortage",
                "slug": "supply-shortage",
                "url": "https://hormuz.group/challenges/market-gaps/supply-shortage/"
            },
            {
                "id": 179,
                "name": "Technology Gap",
                "slug": "technology-gap",
                "url": "https://hormuz.group/challenges/market-gaps/technology-gap/"
            }
        ],
        "company_type": [
            {
                "id": 299,
                "name": "Manufacturer",
                "slug": "manufacturer",
                "url": "https://hormuz.group/company-type/manufacturer/"
            }
        ],
        "city": [
            {
                "id": 423,
                "name": "Tabriz",
                "slug": "tabriz",
                "url": "https://hormuz.group/cities/tabriz/"
            }
        ]
    },
    "taxonomy_labels": {
        "province": "East Azerbaijan",
        "industry": "Healthcare & Pharma, Manufacturing, Pharmaceuticals",
        "market": "Consumer Demand, Healthcare, Materials, Supply Chains",
        "challenges": "Compliance, Import Dependence, Supply Shortage, Technology Gap",
        "company_type": "Manufacturer",
        "city": "Tabriz"
    },
    "fields_summary": {
        "legal_name": "Dana Pharmaceutical Company Public Joint Stock Company",
        "website": "https://www.daanapharma.com",
        "city": "Tabriz, East Azerbaijan Province, Iran",
        "ticker_symbol": "ددانا",
        "listing_status": "listed_ifb",
        "products_services": "Dana Pharmaceutical Company manufactures active pharmaceutical ingredients and finished pharmaceutical products, with emphasis on antibiotic APIs, oral and sterile antibiotics, injectable vials, soft-gel capsules, hard capsules, tablets, oral suspensions, sterile drops, sterile water for injection, eye drops, cardiovascular products, gastrointestinal products, supplements, and selected biotechnology or pharmaceutical development categories.",
        "export_relevance": "high",
        "short_profile": "Dana Pharmaceutical Company is a listed Tabriz-based pharmaceutical manufacturer and one of Iran's major antibiotic and soft-gel producers. In the Hormuz Group company graph, it matters because it connects East Azerbaijan's industrial base, API production, finished antibiotic supply, sterile production, pharmaceutical exports, listed-company disclosure, and import substitution in medicine manufacturing. Its scale makes it relevant to both healthcare access and capital-market monitoring.",
        "investment_relevance": "Dana Pharmaceutical is relevant for investors assessing Iran's listed pharmaceutical sector, antibiotic API localization, sterile-drug capacity, export potential, healthcare supply resilience, and the economics of large drug manufacturers outside Tehran. It can support analysis of medicine shortages, API dependence, pricing regulation, distributor receivables, GMP standards, and foreign-currency exposure. Due diligence should review updated Codal disclosures, production-line utilization, API sourcing, export registrations, product mix, regulatory compliance, quality certifications, working capital, shareholder structure, energy and water reliability, and exposure to sanctions-related payment or supplier constraints."
    },
    "fields": {
        "rank_math_internal_links_processed": "1",
        "wp_statistics_words_count": "0",
        "legal_name": "Dana Pharmaceutical Company Public Joint Stock Company",
        "city": "Tabriz, East Azerbaijan Province, Iran",
        "ticker_symbol": "ددانا",
        "export_relevance": "high",
        "verification_status": "basic",
        "data_confidence": "high",
        "listing_status": "listed_ifb",
        "last_updated": "29/06/2026",
        "website": "https://www.daanapharma.com",
        "products_services": "Dana Pharmaceutical Company manufactures active pharmaceutical ingredients and finished pharmaceutical products, with emphasis on antibiotic APIs, oral and sterile antibiotics, injectable vials, soft-gel capsules, hard capsules, tablets, oral suspensions, sterile drops, sterile water for injection, eye drops, cardiovascular products, gastrointestinal products, supplements, and selected biotechnology or pharmaceutical development categories.",
        "short_profile": "Dana Pharmaceutical Company is a listed Tabriz-based pharmaceutical manufacturer and one of Iran's major antibiotic and soft-gel producers. In the Hormuz Group company graph, it matters because it connects East Azerbaijan's industrial base, API production, finished antibiotic supply, sterile production, pharmaceutical exports, listed-company disclosure, and import substitution in medicine manufacturing. Its scale makes it relevant to both healthcare access and capital-market monitoring.",
        "investment_relevance": "Dana Pharmaceutical is relevant for investors assessing Iran's listed pharmaceutical sector, antibiotic API localization, sterile-drug capacity, export potential, healthcare supply resilience, and the economics of large drug manufacturers outside Tehran. It can support analysis of medicine shortages, API dependence, pricing regulation, distributor receivables, GMP standards, and foreign-currency exposure. Due diligence should review updated Codal disclosures, production-line utilization, API sourcing, export registrations, product mix, regulatory compliance, quality certifications, working capital, shareholder structure, energy and water reliability, and exposure to sanctions-related payment or supplier constraints.",
        "source_note": "Based on public company, official-company, pharmaceutical-sector, API, antibiotic, market, and disclosure-related information. Further verification is required before treating this profile as verified investment intelligence."
    },
    "field_profile": {
        "rank_math_internal_links_processed": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "wp_statistics_words_count": {
            "type": "string",
            "present": true,
            "length": 1
        },
        "legal_name": {
            "type": "string",
            "present": true,
            "length": 54
        },
        "city": {
            "type": "string",
            "present": true,
            "length": 38
        },
        "ticker_symbol": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "export_relevance": {
            "type": "string",
            "present": true,
            "length": 4
        },
        "verification_status": {
            "type": "string",
            "present": true,
            "length": 5
        },
        "data_confidence": {
            "type": "string",
            "present": true,
            "length": 4
        },
        "listing_status": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "last_updated": {
            "type": "string",
            "present": true,
            "length": 10
        },
        "website": {
            "type": "string",
            "present": true,
            "length": 27
        },
        "products_services": {
            "type": "string",
            "present": true,
            "length": 444
        },
        "short_profile": {
            "type": "string",
            "present": true,
            "length": 491
        },
        "investment_relevance": {
            "type": "string",
            "present": true,
            "length": 725
        },
        "source_note": {
            "type": "string",
            "present": true,
            "length": 225
        }
    },
    "sources": [
        {
            "type": "note",
            "value": "Based on public company, official-company, pharmaceutical-sector, API, antibiotic, market, and disclosure-related information. Further verification is required before treating this profile as verified investment intelligence."
        }
    ],
    "quality": {
        "required_fields": [
            "legal_name",
            "website",
            "city",
            "listing_status",
            "products_services",
            "export_relevance",
            "verification_status",
            "data_confidence",
            "short_profile",
            "investment_relevance",
            "source_note",
            "last_updated"
        ],
        "missing_required_fields": [],
        "missing_required_count": 0,
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "29/06/2026",
        "stale_over_180_days": false,
        "quality_score": 100
    },
    "verification": {
        "verification_status": "basic",
        "data_confidence": "high",
        "last_updated": "29/06/2026"
    }
}